Home
Storia in 1 fonti
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R- | Seeking a share of the first-line diffuse B-cell lymphoma market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-CHOP regimen and Roche’s Polivy—that’s at least before newer agents such as T-cell engagers catch up.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s first-line non-small cell lung cancer data for its…
- ·
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw…
- ·
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge…